S-1/A: Scorpius Holdings Eyes $11.1 Million Boost Through Public Offering Amidst NYSE American Relisting

Scorpius Holdings launches a public offering of common stock and pre-funded warrants, aiming to raise $11.1 million, while preparing for a return to trading on the NYSE American.

Summary

• Scorpius Holdings is undertaking a firm commitment public offering of 2,125,850 shares of common stock, with an assumed price of $5.88 per share.
• The company is also offering pre-funded warrants to certain purchasers who would otherwise exceed beneficial ownership limits.
• Each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.0002 per share.
• The company expects net proceeds of approximately $11.1 million, intending to use them for working capital and general corporate purposes.
• The underwriters have a 45-day option to purchase up to 318,878 additional shares or pre-funded warrants to cover over-allotments.
• Scorpius Holdings anticipates resuming trading on the NYSE American on August 2, 2024, under the symbol SCPX, following a reverse stock split.
• The company's common stock previously traded on the OTC Markets after receiving a delisting notice from the NYSE American due to low selling price.
• Preliminary unaudited results for Q2 2024 estimate revenue between $0.3 million and $0.8 million, with an operating loss between $8.6 million and $9.1 million.
• Cash and cash equivalents and short term investments were approximately $1.5 million as of June 30, 2024.
• The company's cash is not expected to last beyond November 2024 unless revenue increases from past historical revenue.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is taking steps to improve its financial position through a public offering and regain its listing on the NYSE American, there are significant concerns about its ability to continue as a going concern and its dependence on a limited number of customers. The preliminary Q2 2024 results also indicate ongoing losses.

Positives

• The company is expected to resume trading on the NYSE American on August 2, 2024, which could improve investor confidence.
• The public offering is expected to provide $11.1 million in net proceeds, which will be used for working capital and general corporate purposes.
• The company has a contract development and manufacturing organization (CDMO) that provides a comprehensive range of biologics manufacturing services.
• The company has a Patent Rights Sale and Assignment Agreement with Kopfkino IP, LLC for $1,000,000.

Negatives

• The company received a delisting notice from the NYSE American due to the low selling price of its common stock.
• The company's cash is not expected to last beyond November 2024 unless revenue increases from past historical revenue.
• The company has incurred significant losses from operations to date and expects its expenses to increase in connection with its ongoing activities.
• The company is dependent on a limited number of customers for a substantial majority of its revenues.
• The estimates of revenue, operating loss, and net loss before income taxes from continuing operations included in this prospectus are preliminary and undue reliance should not be placed on the preliminary estimates.

Risks

• The company's consolidated financial statements have been prepared assuming that it will continue as a going concern, but there is substantial doubt about its ability to do so.
• The company will need additional future financing which may not be available on acceptable terms, if at all.
• The company's securities may be offered to other investors in other offerings at a price lower than the price per share offered in this offering, or upon terms which may be deemed more favorable than those offered to investors in this offering.
• The company's ability to raise capital through the sale of securities may be limited by its inability to utilize a registration statement on Form S-3 to raise capital due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and various rules of the NYSE American that place limits on the number and dollar amount of securities that it may sell.
• This offering may cause the trading price of the company's common stock to decrease.
• There is no public market for the Pre-Funded Warrants being offered in this offering.
• The Pre-Funded Warrants are speculative in nature.
• The company's failure to have its common stock traded on a national securities exchange will adversely impact its common stock.
• The estimates of revenue, operating loss, and net loss before income taxes from continuing operations included in this prospectus are preliminary and undue reliance should not be placed on the preliminary estimates.
• Even though the 2024 Reverse Stock Split increased the market price of the company's common stock, there can be no assurance that its increased stock price will remain at a price that will be sufficient in order to meet any requirements and policies of the NYSE American or that its common stock will remain listed on the NYSE American.
• The 2024 Reverse Stock Split may decrease the liquidity of the shares of the company's common stock.

Future Outlook

The company expects to use the net proceeds from this offering for working capital and general corporate purposes and anticipates resuming trading on the NYSE American on August 2, 2024. The company's cash is not expected to last beyond November 2024 unless revenue increases from past historical revenue.

Industry Context

Scorpius Holdings operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to the increasing complexity of biologics and the need for specialized manufacturing capabilities. The company focuses on celland gene-based therapies as well as large molecule biologics, aligning with current industry trends.

Comparison to Industry Standards

• It's difficult to directly compare Scorpius's preliminary Q2 2024 results without knowing the specific details of their contracts and cost structure.
• However, other CDMOs such as Lonza and Catalent often report higher revenue figures, reflecting their larger scale and broader service offerings.
• For example, Lonza's 2023 revenue was CHF 6.7 billion.
• Scorpius's focus on cell and gene therapies positions it in a high-growth area, but also one with significant competition from specialized CDMOs like WuXi Advanced Therapies and Thermo Fisher Scientific.
• The company's ability to secure larger cGMP manufacturing contracts will be crucial for improving its financial performance and competing effectively in the industry.

Related Party Transactions

• Elusys Holdings, Inc. purchased a convertible promissory note from Scorpius Holdings.
• Scorpius Holdings entered into a Note Purchase Agreement with Elusys Holdings.
• Elusys Holdings forgave repayment of the New Note in exchange for an amendment to the Asset and Equity Interests Purchase Agreement.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees' job security could be affected by the company's financial performance.
• Customers may be concerned about the company's ability to fulfill its contracts.
• Suppliers may face increased risk of non-payment if the company's financial situation does not improve.
• Creditors face increased risk of default if the company's financial situation does not improve.

Next Steps

• Complete the public offering of common stock and pre-funded warrants.
• Resume trading on the NYSE American on August 2, 2024.
• Secure larger cGMP manufacturing contracts to increase revenue.
• Manage expenses to improve financial performance.
• Monitor compliance with NYSE American listing requirements.

Key Dates

Keywords

public offering, pre-funded warrants, common stock, Scorpius Holdings, NYSE American, biologics manufacturing, CDMO, reverse stock split, delisting, ThinkEquity